Financial Assistance Options and Coverage Support

myAgios can connect patients to financial assistance and coverage support programs to help with access to PYRUKYND®, including information about:

The PYRUKYND Copay Program

The PYRUKYND Copay Program lowers costs for eligible patients to $0

  • This program lowers costs for eligible patients to $0 per prescription if their copay exceeds that amount
  • To learn more about patient eligibility, call myAgios Patient Support Services at 1-800-951-3889
  • Patients participating in government healthcare insurance are not eligible

Patient Assistance Program (PAP)

This program may offer free prescriptions to eligible uninsured and underinsured patients. If a patient is uninsured or underinsured, contact their PSM to discuss the options for this patient’s specific case.

  • PAP prescriptions will be reviewed and filled by myAgios if approved
  • If approved, patients must reapply annually and continue to meet income and program eligibility requirements each calendar year

To learn more about patient eligibility requirements, start by calling myAgios at 1-800-951-3889.

Other forms of assistance may be available, including assistance from independent foundations for patients with government insurance or insufficient commercial insurance.

  • Eligibility is determined by the individual foundation
  • Agios is not affiliated with these organizations

Coverage Interruption Program

This program is for eligible commercially insured patients who have filled at least one previous prescription of PYRUKYND and who experience a temporary loss or change in coverage

  • Eligible patients experiencing an interruption in coverage can receive a free 28-day prescription (with up to two refills)
  • Patients participating in government healthcare insurance are not eligible

Please see full Terms and Conditions for more information.

Call myAgios at 1-800-951-3889, Mon-Fri, 8 am to 6 pm ET.


PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.


Acute Hemolysis: Acute hemolysis with subsequent anemia has been observed following abrupt interruption or discontinuation of PYRUKYND in a dose-ranging study. Avoid abruptly discontinuing PYRUKYND. Gradually taper the dose of PYRUKYND to discontinue treatment if possible. When discontinuing treatment, monitor patients for signs of acute hemolysis and anemia including jaundice, scleral icterus, dark urine, dizziness, confusion, fatigue, or shortness of breath.

Adverse Reactions: Serious adverse reactions occurred in 10% of patients receiving PYRUKYND in the ACTIVATE trial, including atrial fibrillation, gastroenteritis, rib fracture, and musculoskeletal pain, each of which occurred in 1 patient. In the ACTIVATE trial, the most common adverse reactions including laboratory abnormalities (≥10%) in patients with PK deficiency were estrone decreased (males), increased urate, back pain, estradiol decreased (males), and arthralgia.

Drug Interactions:

  • Strong CYP3A Inhibitors and Inducers: Avoid concomitant use.
  • Moderate CYP3A Inhibitors: Do not titrate PYRUKYND beyond 20 mg twice daily.
  • Moderate CYP3A Inducers: Consider alternatives that are not moderate inducers. If there are no alternatives, adjust PYRUKYND dosage.
  • Sensitive CYP3A, CYP2B6, CYP2C Substrates Including Hormonal Contraceptives: Avoid concomitant use with substrates that have narrow therapeutic index.
  • UGT1A1 Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.
  • P-gp Substrates: Avoid concomitant use with substrates that have narrow therapeutic index.

Hepatic Impairment: Avoid use of PYRUKYND in patients with moderate and severe hepatic impairment.

Please see full Prescribing Information for PYRUKYND.